Brief: Ose Immunotherapeutics And ARCAGY-GINECO Announce First Patient Randomized In Phase 2 Clinical Trial Evaluating Tedopi® In Combination With Pembrolizumab In Ovarian Cancer
26/08/2021 17:01
Aug 26 (Reuters) - OSE IMMUNOTHERAPEUTICS SA OSE.PA :
* OSE IMMUNOTHERAPEUTICS AND ARCAGY-GINECO ANNOUNCE FIRST
PATIENT
RANDOMIZED IN PHASE 2 CLINICAL TRIAL EVALUATING TEDOPI® IN
COMBINATION WITH PEMBROLIZUMAB IN OVARIAN CANCER
* FIRST RESULTS EXPECTED BEGINNING OF 2025
* PHASE 2 TRIAL IS DESIGNED TO ENROLL 180 PATIENTS AND WILL
BE
CONDUCTED AT APPROXIMATELY 30 SITES IN FRANCE AND AROUND 12
SITES IN GERMANY AND BELGIUM
Source text for Eikon: ID:nBw16XbMxa
Further company coverage: OSE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO